ClinicalTrials.gg
CompletedNCT01905943Updated Oct 28, 2019Results posted

A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia

A Phase 3 interventional study of Bendamustine and Chlorambucil in Chronic Lymphocytic Leukemia, sponsored by Hoffmann-La Roche. Completed at 174 sites in 31 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-28.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
979
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 53 studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell — 16 open to participants now, 28 under way, 6 of them phase 3. obinutuzumab · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
2nd of 53
979 · median 72
Started
2013
with 1 other
Phase 3
13 of 53
4 open now
Registered
6th of 53
by date
Lead sponsor
6 of 53
Hoffmann-La Roche

Among the 53 studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 2nd largest by enrollment, is one of 2 that started in 2013, is one of 13 in phase 3, and was the 6th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

16 of the 53 studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About obinutuzumab

obinutuzumab: first FDA approval 2013 (GAZYVA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This multicenter, open-label, single-arm study will evaluate the safety and efficacy of obinutuzumab alone or in combination with chemotherapy in participants with previously untreated or relapsed/refractory chronic lymphocytic leukemia (CLL). This is a Post-Authorization Safety Study. Participants will receive 6 cycles of single-agent obinutuzumab or obinutuzumab in combination with chemotherapy at the investigator's discretion. Each participant will be followed until 30 months after the last participant has been enrolled. Total length of the study is anticipated to be approximately 5 years.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previously untreated documented CLL according to National Cancer Institute/international workshop on CLL (NCI/iwCLL) criteria OR documented CLL participants requiring treatment according to NCI/iwCLL criteria; participants with up to 3 relapses are eligible
  • Refractory participants if last treatment was with single-agent therapy, single-agent chemotherapy, or single-agent antibody
  • Participants with 17p-deletion and/or p53 mutation may be included at the investigator's discretion
  • (ECOG) performance status 0-2
  • greater than (>) 6 months according to the investigator's opinion
  • Adequate hematological function

Exclusion criteria

Exclusion Criteria:

  • Participants who have received more than 3 previous CLL treatment lines
  • Documented transformation of CLL to aggressive lymphoma (Richter's transformation)
  • Participants who are to immunochemotherapy
  • Participants with abnormal laboratory values
  • One or more individual organ/system impairment score of 4 as assessed by the cumulative illness rating scale (CIRS) definition, excluding the eyes, ears, nose, throat and larynx organ systems
  • Participants with a history of progressive multifocal leukoencephalopathy (PML)
  • History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
  • Known to the study drugs
  • History of prior unless the malignancy has been treated with a curative intent and in remission without treatment for greater than or equal to (>/=) 5 years prior to enrollment and with the exception of curatively-treated basal cell carcinoma, squamous cell carcinoma of the skin, low grade in situ carcinoma of the cervix, or low grade, early stage localized prostate cancer treated surgically with curative intent
  • Regular treatment with during the 28 days prior to the start of Cycle 1, Day 1, unless administered for indications other than CLL at a dose equivalent to less than or equal to (\</=) 30 milligrams per day (mg/day) prednisone
  • Regular treatment with medications following previous organ transplantation
  • Evidence of significant, uncontrolled concomitant diseases
  • Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of the nail beds) or a major episode of infection requiring treatment with intravenous (IV) antibiotics or hospitalization within 28 days prior to the start of Cycle 1, Day 1
  • Vaccination with within 28 days prior to start of Cycle 1, Day 1
  • Major surgery (within 28 days prior to the start of Cycle 1, Day 1), other than for diagnosis
  • Positive for chronic , , human T-lymphotropic virus 1 (HTLV 1) or (HIV) infection
  • Pregnant or lactating women
  • Fertile men or women of
  • Participation in another clinical trial with drug intervention within 28 days prior to start of Cycle 1, Day 1 and during the study
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
979 participants (actual)

Study arms

  • Experimental
    Obinutuzumab

    Participants will receive obinutuzumab either alone as single agent or in combination with chemotherapy (Fludarabine/Cyclophosphamide \[FC\], Bendamustine or Chlorambucil) at the investigator's discretion. Each cycle is of 28-days duration.

    Drug: Bendamustine · Drug: Chlorambucil · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Obinutuzumab

Interventions

  • Bendamustine: 90 milligram per millilitre square (mg/m\^2) IV over 60 minutes once daily (QD) Day 1-2 in participants previously untreated or 70 mg/m\^2 I.V. over 60 minutes QD Day 1-2 in participants with relapsed/refractory disease. In non-fit participants only, investigators may opt at their own discretion to use lower initial doses of bendamustine, i.e., bendamustine 70 mg/m\^2 in previously untreated participants, and bendamustine 50 mg/m\^2 in relapsed/refractory subjects (over 60 minutes qd Day 1-2 for each administration).

  • Chlorambucil 0.5 mg/kg p.o. qd on Day 1 and Day 15 in non-fit participants only.

  • Cyclophosphamide 250 mg/m\^2 I.V. over 15-30 minutes qd Day 1-3 or Cyclophosphamide 250 mg/m\^2 p.o. QD Day 1-3 in fit participants only.

  • Fludarabine 25 mg/m\^2 I.V. over 30 minutes QD Day 1-3 or Fludarabine 40 mg/m\^2 per os (p.o.) QD Day 1-3 in fit participants only.

  • Participants will receive obinutuzumab 1000 mg IV infusion on Days 1/2 (dose split over 2 consecutive days; 100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of cycle 1, and on Day 1 of Cycles 2, 3, 4, 5, and 6. Each cycle is of 28-days duration.

    Also known as: Gazyva®, RO5072759

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs, including AEs of Special Interest and AEs of Particular Interest, were reported based on the national cancer institute common terminology criteria for AEs, Version 4.0 (NCI-CTCAE, v4.0). Reported are the number of subjects with AEs, Grade 3-5 AEs, and Serious Adverse Events (SAEs).

    Time frame: Baseline up to time of primary completion (3 years)

  2. Number of Participants With Adverse Events of Special Interest (AESIs)

    The following AEs were defined as AESIs: AEs with the preferred term Tumour Lysis Syndrome (TLS), Infusion-Related Reactions (IRRs) defined as AEs that occurred during or within 24 hours of the completion of obinutuzumab infusion and were assessed as related to obinutuzumab by the Investigator, Infections defined as AEs from System Organ Class (SOC) "Infections and infestations" and AEs with the preferred term Neutropenia. Reported are number of participants with total AESIs, IRRs, Infections, Neutropenia and TLS.

    Time frame: Baseline up to time of primary completion (3 years)

  3. Number of Participants With Adverse Events of Particular Interest (AEPIs)

    The following AEs were defined as AEPIs: AEs with the preferred term Progressive multifocal leukoencephalopathy (PML), hepatitis B reactivation defined as AEs with preferred term containing "Hepatitis B" or "hepatitis acute", thrombocytopenia defined via Roche MedDRA basket subgroup "haematopoietic thrombocytopenia", second malignancies defined as AEs from the SOC "Neoplasms benign, malignant and unspecified" starting 6 months after the first study drug intake, second malignancies based on standardised MedDRA queries (SMQ) starting 6 months after the first study drug intake based on the MedDRA SMQ "Malignant or unspecified tumours", in which benign neoplasms are not included, Cardiac events including AEs from the SOC "Cardiac disorders", and hemorrhagic events defined via Roche MedDRA basket subgroup "Haemorrhagic events". Reported are number of participants with total AEPIs and each of the AEPI categories.

    Time frame: Baseline up to time of primary completion (3 years)

Secondary outcomes

  1. Percentage of Participants With Overall Response (OR) at Final Response Assessment (FRA)

    OR: percentage of participants with complete response (CR) or CR with incomplete marrow recovery (CRi), or partial response (PR), as determined by the investigator based on International Workshop on Chronic Lymphocytic Leukemia (IWCLL) tumor response criteria. CR: Peripheral blood lymphocytes 4,000/mcL, no significant lymphadenopathy, no hepatomegaly and splenomegaly, no disease symptoms, blood counts: neutrophils \>1,500/mcL, platelets \> 100,000/mcL, hemoglobin \> 110 g/L and bone marrow normocellular for age. Cri: CR with persistent cytopenia. PR: \>/= 50% decrease in peripheral blood lymphocyte count AND \>/= 50% reduction in lymphadenopathy OR \>/= 50% reduction of liver enlargement OR \>/= 50% reduction of spleen PLUS one of the following: neutrophils \>1,500/mcL, platelets \> 100,000/mcL, hemoglobin \> 110 g/L OR \>/= 50% increase in neutrophils, platelets or hemoglobin.

    Time frame: 3 months after the last dose of study treatment (up to approximately 5 years)

  2. Percentage of Participants With Minimal Residual Disease (MRD)-Negativity as Assessed by Flow Cytometry

    MRD-negativity was defined as the presence of less than 1 chronic lymphocytic leukemia (CLL) cell per 10,000 leukocytes in blood and bone marrow as assessed by flow cytometry 3 months after last dose of study treatment (i.e. at final response assessment \[FRA\] visit).

    Time frame: 3 months after the last dose of study treatment (up to approximately 5 years)

  3. Percentage of Participants With Best Overall Response (BOR)

    BOR was defined as the percentage of participants with the best response obtained throughout the trial with CR, CRi, or PR, as determined by the investigator based on IWCLL tumor response criteria. CR: Peripheral blood lymphocytes 4,000/mcL, no significant lymphadenopathy, no hepatomegaly and splenomegaly, no disease symptoms, blood counts: neutrophils \>1,500/mcL, platelets \> 100,000/mcL, hemoglobin \> 110 g/L and bone marrow normocellular for age. Cri: CR with persistent cytopenia. PR: \>/= 50% decrease in peripheral blood lymphocyte count AND \>/= 50% reduction in lymphadenopathy OR \>/= 50% reduction of liver enlargement OR \>/= 50% reduction of spleen PLUS one of the following: neutrophils \>1,500/mcL, platelets \> 100,000/mcL, hemoglobin \> 110 g/L OR \>/= 50% increase in neutrophils, platelets or hemoglobin.

    Time frame: Baseline, Day 85, end of treatment or early termination, and follow-up, assessed up to disease progression or death, whichever occurs first (up to approximately 5 years)

  4. Median Time to Progression-Free Survival (PFS)

    Kaplan Meier estimate of the median PFS was defined as the time at which half of the participants have progressed (progressive disease \[PD\]) based on IWCLL tumor response criteria or died from any cause, whichever occurred first. PD: at least one of the following: \>/= 50% increase in the absolute number of circulating lymphocytes to at least 5,000/mcL, appearance of new palpable lymph nodes, \>/= 50% increase in the longest diameter of any previous site of clinically significant lymphadenopathy, \>/= 50% increase in the enlargement of the liver and/or spleen, transformation to more aggressive histology, progression of any cytopenia, decrease of hemoglobin levels by more than 20 g/L or to less than 100 g/L, decrease of platelet counts by more than 50% or to less than 100,000 /mcL, decrease of neutrophil counts by more than 50% or to less than 1,000/mcL.

    Time frame: Baseline, Day 85, end of treatment or early termination, and follow-up, assessed up to disease progression or death, whichever occurs first (up to approximately 5 years)

  5. Median Time to Response (TTR)

    Kaplan Meier estimate of median TTR was defined as the time at which half of the participants reached CR or PR based on IWCLL tumor response criteria. CR: Peripheral blood lymphocytes 4,000/mcL, no significant lymphadenopathy, no hepatomegaly and splenomegaly, no disease symptoms, blood counts: neutrophils \>1,500/mcL, platelets \> 100,000/mcL, hemoglobin \> 110 g/L and bone marrow normocellular for age. PR: \>/= 50% decrease in peripheral blood lymphocyte count AND \>/= 50% reduction in lymphadenopathy OR \>/= 50% reduction of liver enlargement OR \>/= 50% reduction of spleen PLUS one of the following: neutrophils \>1,500/mcL, platelets \> 100,000/mcL, hemoglobin \> 110 g/L OR \>/= 50% increase in neutrophils, platelets or hemoglobin.

    Time frame: Baseline, Day 85, end of treatment or early termination, and follow-up, assessed up to disease progression or death, whichever occurs first (up to approximately 5 years)

  6. Median Time to Event-Free Survival (EFS)

    Kaplan Meier estimate of median EFS is the time at which half of the participants have progressed as assessed by investigator based on IWCLL tumor response criteria, or have initiated a non-protocol-specified anti-leukemia therapy or died, whichever occurs first. PD: at least 1 of the following: \>/= 50% increase in absolute number of circulating lymphocytes to at least 5,000/mcL, appearance of new palpable lymph nodes, \>/= 50% increase in longest diameter of any previous site of clinically significant lymphadenopathy, \>/= 50% increase in enlargement of liver and/or spleen, transformation to more aggressive histology, progression of any cytopenia, decrease of hemoglobin levels by more than 20 g/L or to less than 100 g/L, decrease of platelet counts by more than 50% or to less than 100,000 /mcL, decrease of neutrophil counts by more than 50% or to less than 1,000/mcL.

    Time frame: Baseline, Day 85, end of treatment or early termination, and follow-up, assessed up to disease progression or death, whichever occurs first (up to approximately 5 years)

  7. Median Time to Overall Survival (OS)

    Kaplan Meier estimate of median OS was defined as the time at which half of the participants had died, regardless of the cause of death.

    Time frame: Baseline until death (Approximately up to 5 years)

  8. Median Time to New Anti-Leukemia Therapy (TTNT)

    Kaplan Meier estimate of median TTNT was defined as the time at which half of the participants have initiated a new anti-leukemic therapy.

    Time frame: Baseline until end of study (up to approximately 5 years)

  9. Median Time to Duration of Response (DoR)

    Kaplan Meier estimate of median DoR was defined as the time at which half of the responding (PR or CR) participants had progressed (PD) or died from any cause, whichever occurred first. PR: \>/= 50% decrease in peripheral blood lymphocyte count AND \>/= 50% reduction in lymphadenopathy OR \>/= 50% reduction of liver enlargement OR \>/= 50% reduction of spleen PLUS one of the following: neutrophils \>1,500/mcL, platelets \> 100,000/mcL, hemoglobin \> 110 g/L OR \>/= 50% increase in neutrophils, platelets or hemoglobin. CR: Peripheral blood lymphocytes 4,000/mcL, no significant lymphadenopathy, no hepatomegaly and splenomegaly, no disease symptoms, blood counts: neutrophils \>1,500/mcL, platelets \> 100,000/mcL, hemoglobin \> 110 g/L and bone marrow normocellular for age. PD: as defined in the description for Event-Free Survival outcome measure.

    Time frame: Baseline, Day 85, end of treatment or early termination, and follow-up, assessed up to disease progression or death, whichever occurs first (up to approximately 5 years)

07

Results

Posted Oct 29, 2018

Participant flow

The study was conducted at 195 centers in 31 countries

Participant flow — Overall Study
MilestoneObinutuzumab
Started972
Completed658
Not completed314
Withdrew: Withdrawal of consent90
Withdrew: Lost to follow-up16
Withdrew: Investigator discretion7
Withdrew: Death186
Withdrew: Adverse event3
Withdrew: Other12

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs)

An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs, including AEs of Special Interest and AEs of Particular Interest, were reported based on the national cancer institute common terminology criteria for AEs, Version 4.0 (NCI-CTCAE, v4.0). Reported are the number of subjects with AEs, Grade 3-5 AEs, and Serious Adverse Events (SAEs).

Time frame:
Baseline up to time of primary completion (3 years)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsObinutuzumab
AEs950
Grade 3-5 AEs780
SAEs516
PrimaryNumber of Participants With Adverse Events of Special Interest (AESIs)

The following AEs were defined as AESIs: AEs with the preferred term Tumour Lysis Syndrome (TLS), Infusion-Related Reactions (IRRs) defined as AEs that occurred during or within 24 hours of the completion of obinutuzumab infusion and were assessed as related to obinutuzumab by the Investigator, Infections defined as AEs from System Organ Class (SOC) "Infections and infestations" and AEs with the preferred term Neutropenia. Reported are number of participants with total AESIs, IRRs, Infections, Neutropenia and TLS.

Time frame:
Baseline up to time of primary completion (3 years)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events of Special Interest (AESIs)
ParticipantsObinutuzumab
Total AESIs905
IRRs635
Neutropenia599
Infections521
TLS62
PrimaryNumber of Participants With Adverse Events of Particular Interest (AEPIs)

The following AEs were defined as AEPIs: AEs with the preferred term Progressive multifocal leukoencephalopathy (PML), hepatitis B reactivation defined as AEs with preferred term containing "Hepatitis B" or "hepatitis acute", thrombocytopenia defined via Roche MedDRA basket subgroup "haematopoietic thrombocytopenia", second malignancies defined as AEs from the SOC "Neoplasms benign, malignant and unspecified" starting 6 months after the first study drug intake, second malignancies based on standardised MedDRA queries (SMQ) starting 6 months after the first study drug intake based on the MedDRA SMQ "Malignant or unspecified tumours", in which benign neoplasms are not included, Cardiac events including AEs from the SOC "Cardiac disorders", and hemorrhagic events defined via Roche MedDRA basket subgroup "Haemorrhagic events". Reported are number of participants with total AEPIs and each of the AEPI categories.

Time frame:
Baseline up to time of primary completion (3 years)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events of Particular Interest (AEPIs)
ParticipantsObinutuzumab
Total AEPIs467
Thrombocytopenia314
Cardiac events109
Second malignancies82
Second malignancies (SMQ)75
Hemorrhagic events69
Hepatitis B reactivation3
PML1
SecondaryPercentage of Participants With Overall Response (OR) at Final Response Assessment (FRA)

OR: percentage of participants with complete response (CR) or CR with incomplete marrow recovery (CRi), or partial response (PR), as determined by the investigator based on International Workshop on Chronic Lymphocytic Leukemia (IWCLL) tumor response criteria. CR: Peripheral blood lymphocytes 4,000/mcL, no significant lymphadenopathy, no hepatomegaly and splenomegaly, no disease symptoms, blood counts: neutrophils \>1,500/mcL, platelets \> 100,000/mcL, hemoglobin \> 110 g/L and bone marrow normocellular for age. Cri: CR with persistent cytopenia. PR: \>/= 50% decrease in peripheral blood lymphocyte count AND \>/= 50% reduction in lymphadenopathy OR \>/= 50% reduction of liver enlargement OR \>/= 50% reduction of spleen PLUS one of the following: neutrophils \>1,500/mcL, platelets \> 100,000/mcL, hemoglobin \> 110 g/L OR \>/= 50% increase in neutrophils, platelets or hemoglobin.

Time frame:
3 months after the last dose of study treatment (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Overall Response (OR) at Final Response Assessment (FRA)
percentage of participantsG Mono: Previously Untreated FitG Mono: Previously Untreated UnfitG Mono: Relapsed/RefractoryG-Benda: Previously Untreated FitG-Benda: Previously Untreated UnfitG-Benda: Relapsed/RefractoryG-FC: Previously Untreated FitG-FC: Previously Untreated UnfitG-FC: Relapsed/RefractoryG-Clb: Previously Untreated FitG-Clb: Previously Untreated UnfitG-Clb: Relapsed/Refractory
Percentage of Participants With Overall Response (OR) at Final Response Assessment (FRA)71.0 (52.0 to 85.8)59.4 (40.6 to 76.3)41.5 (29.4 to 54.4)83.9 (77.5 to 89.1)81.6 (75.1 to 87.0)73.2 (66.3 to 79.3)90.0 (83.8 to 94.4)84.6 (54.6 to 98.1)85.0 (70.2 to 94.3)100 (2.5 to 100.0)82.1 (70.8 to 90.4)56.5 (41.1 to 71.1)
SecondaryPercentage of Participants With Minimal Residual Disease (MRD)-Negativity as Assessed by Flow Cytometry

MRD-negativity was defined as the presence of less than 1 chronic lymphocytic leukemia (CLL) cell per 10,000 leukocytes in blood and bone marrow as assessed by flow cytometry 3 months after last dose of study treatment (i.e. at final response assessment \[FRA\] visit).

Time frame:
3 months after the last dose of study treatment (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Minimal Residual Disease (MRD)-Negativity as Assessed by Flow Cytometry
percentage of participantsG Mono: Previously Untreated FitG Mono: Previously Untreated UnfitG Mono: Relapsed/RefractoryG-Benda: Previously Untreated FitG-Benda: Previously Untreated UnfitG-Benda: Relapsed/RefractoryG-FC: Previously Untreated FitG-FC: Previously Untreated UnfitG-FC: Relapsed/RefractoryG-Clb: Previously Untreated FitG-Clb: Previously Untreated UnfitG-Clb: Relapsed/Refractory
Blood8.323.14.163.165.339.872.058.351.5—9.46.3
Bone Marrow4.23.82.031.527.214.940.041.724.2—5.73.1
SecondaryPercentage of Participants With Best Overall Response (BOR)

BOR was defined as the percentage of participants with the best response obtained throughout the trial with CR, CRi, or PR, as determined by the investigator based on IWCLL tumor response criteria. CR: Peripheral blood lymphocytes 4,000/mcL, no significant lymphadenopathy, no hepatomegaly and splenomegaly, no disease symptoms, blood counts: neutrophils \>1,500/mcL, platelets \> 100,000/mcL, hemoglobin \> 110 g/L and bone marrow normocellular for age. Cri: CR with persistent cytopenia. PR: \>/= 50% decrease in peripheral blood lymphocyte count AND \>/= 50% reduction in lymphadenopathy OR \>/= 50% reduction of liver enlargement OR \>/= 50% reduction of spleen PLUS one of the following: neutrophils \>1,500/mcL, platelets \> 100,000/mcL, hemoglobin \> 110 g/L OR \>/= 50% increase in neutrophils, platelets or hemoglobin.

Time frame:
Baseline, Day 85, end of treatment or early termination, and follow-up, assessed up to disease progression or death, whichever occurs first (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Best Overall Response (BOR)
percentage of participantsG Mono: Previously Untreated FitG Mono: Previously Untreated UnfitG Mono: Relapsed/RefractoryG-Benda: Previously Untreated FitG-Benda: Previously Untreated UnfitG-Benda: Relapsed/RefractoryG-FC: Previously Untreated FitG-FC: Previously Untreated UnfitG-FC: Relapsed/RefractoryG-Clb: Previously Untreated FitG-Clb: Previously Untreated UnfitG-Clb: Relapsed/Refractory
Percentage of Participants With Best Overall Response (BOR)83.9 (66.3 to 94.5)71.9 (53.3 to 86.3)60.0 (47.1 to 72.0)91.7 (86.4 to 95.4)93.9 (89.3 to 96.9)86.8 (81.2 to 91.3)97.1 (92.8 to 99.2)84.6 (54.6 to 98.1)97.5 (86.8 to 99.9)100 (2.5 to 100.0)94.0 (85.4 to 98.3)84.8 (71.1 to 93.7)
SecondaryMedian Time to Progression-Free Survival (PFS)

Kaplan Meier estimate of the median PFS was defined as the time at which half of the participants have progressed (progressive disease \[PD\]) based on IWCLL tumor response criteria or died from any cause, whichever occurred first. PD: at least one of the following: \>/= 50% increase in the absolute number of circulating lymphocytes to at least 5,000/mcL, appearance of new palpable lymph nodes, \>/= 50% increase in the longest diameter of any previous site of clinically significant lymphadenopathy, \>/= 50% increase in the enlargement of the liver and/or spleen, transformation to more aggressive histology, progression of any cytopenia, decrease of hemoglobin levels by more than 20 g/L or to less than 100 g/L, decrease of platelet counts by more than 50% or to less than 100,000 /mcL, decrease of neutrophil counts by more than 50% or to less than 1,000/mcL.

Time frame:
Baseline, Day 85, end of treatment or early termination, and follow-up, assessed up to disease progression or death, whichever occurs first (up to approximately 5 years)
Reported as:
Median · months
Median Time to Progression-Free Survival (PFS)
monthsG Mono: Previously Untreated FitG Mono: Previously Untreated UnfitG Mono: Relapsed/RefractoryG-Benda: Previously Untreated FitG-Benda: Previously Untreated UnfitG-Benda: Relapsed/RefractoryG-FC: Previously Untreated FitG-FC: Previously Untreated UnfitG-FC: Relapsed/RefractoryG-Clb: Previously Untreated FitG-Clb: Previously Untreated UnfitG-Clb: Relapsed/Refractory
Median Time to Progression-Free Survival (PFS)43.0 (17.0 to NA)21.2 (14.9 to NA)17.6 (12.5 to 20.0)58.0 (44.5 to 58.0)NA (45.4 to NA)28.6 (24.2 to 31.1)NA (53.7 to NA)NA (19.0 to NA)24.8 (19.3 to 35.0)31.3 (NA to NA)31.8 (27.7 to 36.4)14.1 (10.8 to 22.1)
SecondaryMedian Time to Response (TTR)

Kaplan Meier estimate of median TTR was defined as the time at which half of the participants reached CR or PR based on IWCLL tumor response criteria. CR: Peripheral blood lymphocytes 4,000/mcL, no significant lymphadenopathy, no hepatomegaly and splenomegaly, no disease symptoms, blood counts: neutrophils \>1,500/mcL, platelets \> 100,000/mcL, hemoglobin \> 110 g/L and bone marrow normocellular for age. PR: \>/= 50% decrease in peripheral blood lymphocyte count AND \>/= 50% reduction in lymphadenopathy OR \>/= 50% reduction of liver enlargement OR \>/= 50% reduction of spleen PLUS one of the following: neutrophils \>1,500/mcL, platelets \> 100,000/mcL, hemoglobin \> 110 g/L OR \>/= 50% increase in neutrophils, platelets or hemoglobin.

Time frame:
Baseline, Day 85, end of treatment or early termination, and follow-up, assessed up to disease progression or death, whichever occurs first (up to approximately 5 years)
Reported as:
Median · months
Median Time to Response (TTR)
monthsG Mono: Previously Untreated FitG Mono: Previously Untreated UnfitG Mono: Relapsed/RefractoryG-Benda: Previously Untreated FitG-Benda: Previously Untreated UnfitG-Benda: Relapsed/RefractoryG-FC: Previously Untreated FitG-FC: Previously Untreated UnfitG-FC: Relapsed/RefractoryG-Clb: Previously Untreated FitG-Clb: Previously Untreated UnfitG-Clb: Relapsed/Refractory
Median Time to Response (TTR)3.6 (3.2 to 3.8)3.6 (3.3 to 3.9)3.9 (3.7 to 4.4)3.5 (3.4 to 3.6)3.5 (3.5 to 3.7)3.7 (3.5 to 3.7)3.6 (3.5 to 3.7)4.1 (3.3 to 7.9)3.6 (3.4 to 3.7)3.3 (NA to NA)3.6 (3.4 to 3.7)3.7 (3.5 to 3.8)
SecondaryMedian Time to Event-Free Survival (EFS)

Kaplan Meier estimate of median EFS is the time at which half of the participants have progressed as assessed by investigator based on IWCLL tumor response criteria, or have initiated a non-protocol-specified anti-leukemia therapy or died, whichever occurs first. PD: at least 1 of the following: \>/= 50% increase in absolute number of circulating lymphocytes to at least 5,000/mcL, appearance of new palpable lymph nodes, \>/= 50% increase in longest diameter of any previous site of clinically significant lymphadenopathy, \>/= 50% increase in enlargement of liver and/or spleen, transformation to more aggressive histology, progression of any cytopenia, decrease of hemoglobin levels by more than 20 g/L or to less than 100 g/L, decrease of platelet counts by more than 50% or to less than 100,000 /mcL, decrease of neutrophil counts by more than 50% or to less than 1,000/mcL.

Time frame:
Baseline, Day 85, end of treatment or early termination, and follow-up, assessed up to disease progression or death, whichever occurs first (up to approximately 5 years)
Reported as:
Median · months
Median Time to Event-Free Survival (EFS)
monthsG Mono: Previously Untreated FitG Mono: Previously Untreated UnfitG Mono: Relapsed/RefractoryG-Benda: Previously Untreated FitG-Benda: Previously Untreated UnfitG-Benda: Relapsed/RefractoryG-FC: Previously Untreated FitG-FC: Previously Untreated UnfitG-FC: Relapsed/RefractoryG-Clb: Previously Untreated FitG-Clb: Previously Untreated UnfitG-Clb: Relapsed/Refractory
Median Time to Event-Free Survival (EFS)35.2 (15.6 to NA)17.9 (14.5 to NA)14.0 (9.1 to 17.9)58.0 (44.5 to 58.0)52.9 (44.7 to NA)25.1 (21.0 to 30.4)NA (53.7 to NA)NA (17.8 to NA)24.2 (18.7 to 33.8)31.3 (NA to NA)31.8 (27.7 to 36.4)13.7 (10.5 to 18.0)
SecondaryMedian Time to Overall Survival (OS)

Kaplan Meier estimate of median OS was defined as the time at which half of the participants had died, regardless of the cause of death.

Time frame:
Baseline until death (Approximately up to 5 years)
Reported as:
Median · months
Median Time to Overall Survival (OS)
monthsG Mono: Previously Untreated FitG Mono: Previously Untreated UnfitG Mono: Relapsed/RefractoryG-Benda: Previously Untreated FitG-Benda: Previously Untreated UnfitG-Benda: Relapsed/RefractoryG-FC: Previously Untreated FitG-FC: Previously Untreated UnfitG-FC: Relapsed/RefractoryG-Clb: Previously Untreated FitG-Clb: Previously Untreated UnfitG-Clb: Relapsed/Refractory
Median Time to Overall Survival (OS)NA (NA to NA)NA (40.7 to NA)NA (42.1 to NA)NA (NA to NA)NA (NA to NA)NA (55.3 to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (35.2 to NA)
SecondaryMedian Time to New Anti-Leukemia Therapy (TTNT)

Kaplan Meier estimate of median TTNT was defined as the time at which half of the participants have initiated a new anti-leukemic therapy.

Time frame:
Baseline until end of study (up to approximately 5 years)
Reported as:
Median · months
Median Time to New Anti-Leukemia Therapy (TTNT)
monthsG Mono: Previously Untreated FitG Mono: Previously Untreated UnfitG Mono: Relapsed/RefractoryG-Benda: Previously Untreated FitG-Benda: Previously Untreated UnfitG-Benda: Relapsed/RefractoryG-FC: Previously Untreated FitG-FC: Previously Untreated UnfitG-FC: Relapsed/RefractoryG-Clb: Previously Untreated FitG-Clb: Previously Untreated UnfitG-Clb: Relapsed/Refractory
Median Time to New Anti-Leukemia Therapy (TTNT)NA (25.0 to NA)NA (27.5 to NA)22.5 (14.8 to 27.0)NA (53.5 to NA)NA (NA to NA)38.3 (31.5 to 42.0)NA (NA to NA)NA (35.0 to NA)32.6 (28.2 to NA)NA (NA to NA)53.7 (37.1 to NA)20.4 (13.7 to 43.3)
SecondaryMedian Time to Duration of Response (DoR)

Kaplan Meier estimate of median DoR was defined as the time at which half of the responding (PR or CR) participants had progressed (PD) or died from any cause, whichever occurred first. PR: \>/= 50% decrease in peripheral blood lymphocyte count AND \>/= 50% reduction in lymphadenopathy OR \>/= 50% reduction of liver enlargement OR \>/= 50% reduction of spleen PLUS one of the following: neutrophils \>1,500/mcL, platelets \> 100,000/mcL, hemoglobin \> 110 g/L OR \>/= 50% increase in neutrophils, platelets or hemoglobin. CR: Peripheral blood lymphocytes 4,000/mcL, no significant lymphadenopathy, no hepatomegaly and splenomegaly, no disease symptoms, blood counts: neutrophils \>1,500/mcL, platelets \> 100,000/mcL, hemoglobin \> 110 g/L and bone marrow normocellular for age. PD: as defined in the description for Event-Free Survival outcome measure.

Time frame:
Baseline, Day 85, end of treatment or early termination, and follow-up, assessed up to disease progression or death, whichever occurs first (up to approximately 5 years)
Reported as:
Median · months
Median Time to Duration of Response (DoR)
monthsG Mono: Previously Untreated FitG Mono: Previously Untreated UnfitG Mono: Relapsed/RefractoryG-Benda: Previously Untreated FitG-Benda: Previously Untreated UnfitG-Benda: Relapsed/RefractoryG-FC: Previously Untreated FitG-FC: Previously Untreated UnfitG-FC: Relapsed/RefractoryG-Clb: Previously Untreated FitG-Clb: Previously Untreated UnfitG-Clb: Relapsed/Refractory
Median Time to Duration of Response (DoR)40.1 (26.3 to NA)20.1 (12.1 to NA)15.0 (12.1 to 19.9)55.0 (44.2 to 55.0)49.3 (44.2 to NA)25.5 (21.2 to 29.7)NA (50.1 to NA)NA (48.3 to NA)21.2 (15.1 to 32.1)28.1 (NA to NA)28.1 (24.3 to 34.8)12.3 (7.3 to 20.6)

Adverse events

Collected over Up to 5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
G-Mono—71/127 (55.9%)108/127 (85%)
G-Benda—335/537 (62.4%)503/537 (93.7%)
G-FC—107/193 (55.4%)184/193 (95.3%)
G-Clb—66/114 (57.9%)107/114 (93.9%)
Most frequent serious events
Showing 10 of 404
Most frequent serious events
EventG-MonoG-BendaG-FCG-Clb
PneumoniaInfections and infestations12/12765/53715/19317/114
NeutropeniaBlood and lymphatic system disorders9/12762/53728/1936/114
Febrile neutropeniaBlood and lymphatic system disorders7/12743/53720/1933/114
PyrexiaGeneral disorders4/12723/53711/1932/114
Tumour lysis syndromeMetabolism and nutrition disorders2/12730/5373/1933/114
ThrombocytopeniaBlood and lymphatic system disorders2/12717/5376/1935/114
Cytokine release syndromeImmune system disorders5/1271/5372/1930/114
Lung infectionInfections and infestations0/1275/5377/1932/114
DeathGeneral disorders2/1277/5371/1934/114
Anaphylactic reactionImmune system disorders4/1271/5370/1930/114
Most frequent other events
Showing 10 of 41
Most frequent other events
EventG-MonoG-BendaG-FCG-Clb
NeutropeniaBlood and lymphatic system disorders45/127288/537138/19358/114
NauseaGastrointestinal disorders23/127144/53775/19326/114
ThrombocytopeniaBlood and lymphatic system disorders27/127162/53767/19334/114
PyrexiaGeneral disorders28/127173/53761/19328/114
AnaemiaBlood and lymphatic system disorders19/127134/53750/19327/114
VomitingGastrointestinal disorders9/12768/53744/19315/114
FatigueGeneral disorders7/12771/53719/19323/114
DiarrhoeaGastrointestinal disorders6/12783/53738/19311/114
ChillsGeneral disorders18/12792/53730/19319/114
AstheniaGeneral disorders8/12748/53730/19314/114

Baseline characteristics

The intent-to-treat (ITT) population was defined as all participants enrolled in the study regardless of whether or not they received any study drug.

Age, Continuous
Age, Continuous(years)Obinutuzumab
Mean65.4 ± 10.94
Sex: Female, Male
Sex: Female, Male(Participants)Obinutuzumab
Female355
Male617
08

Study locations

174 sites
  • Hospital Iturraspe
    Santa Fé, 3000, Argentina
  • Hospital Erasme; Neurologie
    Bruxelles, 1070, Belgium
  • Cliniques Universitaires St-Luc
    Bruxelles, 1200, Belgium
  • Jessa Zkh (Campus Virga Jesse)
    Hasselt, 3500, Belgium
  • CHU Sart-Tilman
    Liège, 4000, Belgium
  • Sint Augustinus Wilrijk
    Wilrijk, 2610, Belgium
  • University Clinical Center of the Republic of Srpska, Clinic for Internal Disease, Hematology Dept
    Banja Luka, 88000, Bosnia and Herzegovina
  • University Clinical Center Sarajevo, Clinic for Hematology
    Sarajevo, 71000, Bosnia and Herzegovina
  • Hospital das Clinicas - UFRGS
    Porto Alegre, RS 90035-903, Brazil
  • Hospital de Cancer de Barretos
    Barretos, SP 14784-400, Brazil
  • Hospital Amaral Carvalho
    Jau, SP 17210-120, Brazil
  • Instituto de Ensino e Pesquisa Sao Lucas - IEP
    Sao Paulo, SP 01236-030, Brazil
  • Hospital Sirio Libanes; Centro de Oncologia
    Sao Paulo, SP 01308-050, Brazil
  • Hospital Estadual do Servidor Publico; Hematologia
    Sao Paulo, SP 04029-000, Brazil
  • Hospital das Clinicas - FMUSP; Hematologia
    Sao Paulo, SP 05403-000, Brazil
  • Hospital Santa Marcelina;Oncologia
    Sao Paulo, SP 08270-070, Brazil
  • Cancer Care Manitoba
    Winnipeg, Manitoba R3E 0V9, Canada
  • Regional health authority A vitalite health network
    Moncton, New Brunswick E1C 8X3, Canada
  • Queen Elizabeth II Health Sciences Centre; Oncology
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Royal Victoria Regional Health Centre; c/o Oncology Clinical Trials
    Barrie, Ontario L4M 6M2, Canada
  • Hopital Charles Lemoyne; Centre Integre de Lutte Contre Le Cancer de La Monteregie
    Greenfield Park, Quebec J4V 2H1, Canada
  • Hopital Maisonneuve- Rosemont; Oncology
    Montreal, Quebec H1T 2M4, Canada
  • Centre de sante et de services sociaux Rimouski Neigette
    Rimouski, Quebec G5L 5T1, Canada
  • Saskatoon Cancer Centre; Uni of Saskatoon Campus
    Saskatoon, Saskatchewan S7N 4H4, Canada
  • CHU de Quebec - Hopital de l'Enfant-Jesus; Unite de Recherche en Hematologie et Oncologie
    Quebec, G1J 1Z4, Canada
  • Cairo University Hospital Al Kasr El Ainy
    Cairo, 11559, Egypt
  • National Cancer Institute
    Cairo, 11796, Egypt
  • North Estonia Regional Hospital; Hematology
    Tallinn, 13419, Estonia
  • Tartu Uni Hospital; Hematology - Oncology Clinic
    Tartu, 51014, Estonia
  • Kuopio University Hospital
    Kuopio, 70211, Finland
  • Tampere University Hospital; Hematology
    Tampere, 33521, Finland
  • Turku Uni Central Hospital; Dept of Internal Medicine
    Turku, 20520, Finland
  • Hotel Dieu; Medecine D
    Angers, 49933, France
  • Ch Victor Dupouy; Hematologie
    Argenteuil, 95107, France
  • Hopital Augustin Morvan; Hematologie
    Brest, 29609, France
  • Hopital Cote De Nacre; Hematologie Biologique
    Caen, 14033, France
  • Chu Estaing; Hematologie Clinique Adultes
    Clermont Ferrand, 63003, France
  • Hopital Henri Mondor; Hematologie Clinique
    Creteil, 94010, France
  • Chu Site Du Bocage;Hematologie Clinique
    Dijon, 21079, France
  • Centre Hospitalier Departemental Les Oudairies
    La Roche Sur Yon, 85925, France
  • Ch Du Mans; Medecine Hematologie Oncologie
    Le Mans, 72037, France
  • Hopital Claude Huriez; Hematologie
    Lille, 59037, France
  • Hopital Uni Ire Dupuytren; Hematologie
    Limoges, 87042, France
  • Hopital Saint Eloi; Hematologie Oncologie Medicale
    Montpellier, 34295, France
  • Hopital Emile Muller; Hematologie
    Mulhouse, 68070, France
  • Hopital Hotel Dieu Et Hme;Hopital De Jour
    Nantes, 44093, France
  • Hopital Saint Louis ; Service d Oncologie Medicale Fougere 6 (Pr Misset)
    Paris, 75475, France
  • Hopital Saint Antoine; Hematologie Clinique
    Paris, 75571, France
  • Hopital Pitie Salpetriere; Hematologie Clinique
    Paris, 75651, France
  • Hopital Saint Jean; Hematologie
    Perpignan, 66046, France
  • Hopital De Haut Leveque; Hematologie Clinique
    Pessac, 33604, France
  • Ch Lyon Sud; Hemato Secteur Jules Courmont
    Pierre Benite, 69495, France
  • Centre Hospitalier René Dubos; Hematologie
    Pontoise, 95300, France
  • Hopital Robert Debre; Hematologie Clinique
    Reims, 51092, France
  • Centre Henri Becquerel; Hematologie
    Rouen, 76038, France
  • Centre Hospitalier de Saint Brieuc - Hôpital Yves Le Foll
    St Brieuc, 22027, France
  • Hopital Bretonneau; Hematologie Therapie Cellulaire
    Tours, 37044, France
  • Hämatologisch-onkologische Praxis Dr. med. - Heinrich, - Bangerter
    Augsburg, 86150, Germany
  • BAG Freiberg-Richter, Jacobasch, Illmer, Wolf; Gemeinschaftspraxis Hämatologie-Onkologie
    Dresden, 01307, Germany
  • Gemeinschaftspraxis; Prof. Dr. Michael Kiehl und Dr.med. Wolfgang Stein
    Frankfurt an der Oder, 15236, Germany
  • Onkologisches Zentrum am Bethanien-Kankenhaus
    Frankfurt, 60389, Germany
  • Dres.Andreas Ammon und Dirk Meyer
    Göttingen, 37073, Germany
  • OncoResearch Lerchenfeld GmbH
    Hamburg, 22081, Germany
  • Onkologische Schwerpunktpraxis Lübeck
    Lübeck, 23562, Germany
  • Onkologische Gemeinschaftspraxis
    Magdeburg, 39104, Germany
  • Kliniken Ostalb, Stauferklinikum Schwäbisch-Gmünd; Zentrum für Innere Medizin
    Mutlangen, 73557, Germany
  • Dres. Hans-Dieter Schick Dorothea Schick Burkhard Schmidt u.w.
    München, 81241, Germany
  • Gemeinschaftspraxis Dr. med. Holger Klaproth / Dr. med. Anca Astrid Cura
    Neunkirchen/Saar, 66538, Germany
  • eps - early phase GmbH
    Pößneck, 07381, Germany
  • Oncologianova GmbH - Gesellschaft für Innovationen in der Onkologie
    Recklinghausen, 45659, Germany
  • Schwerpunktpraxis & Tagesklinik f. Hämatologie & Onkologie Regensdorf / Schwandorf / Wörth
    Regensburg, 93053, Germany
  • Universitätsklinikum Ulm; Medizinische Uni-Klinik III Abt. Innere Medizin III Hämatologie u. Onkolo.
    Ulm, 89081, Germany
  • Onkologische Schwerpunktpraxis Dres. Rudolf Schlag und Björn Schöttker
    Würzburg, 97080, Germany
  • General Hospital of Athens Evangelismos; Hematology
    Athens, 106 76, Greece
  • Laiko General Hospital of Athens; A Propedeutical Clinic of Internal Medicine
    Athens, 115 27, Greece
  • Laiko General Hospital; Hematology Clinic
    Athens, 115 27, Greece
  • University Hospital of Ioannina; Hematology
    Ioannina, 455 00, Greece
  • Georgios Papanikolaou Hospital; Hematology Department
    Thessaloniki, 570 10, Greece
  • Mater Misericordiae Uni Hospital; Oncology
    Dublin, 7, Ireland
  • University Hospital Limerick - Oncology
    Limerick, Ireland
  • Waterford Regional Hospital; Department Of Medical Oncology
    Waterford, Ireland
  • Soroka Medical Center; Hematology Deptartment
    Beer Sheva, 8410101, Israel
  • Bnei-Zion Medical Center; Hematology Dept
    Haifa, 3339419, Israel
  • Hadassah Ein Karem Hospital; Haematology
    Jerusalem, 9112001, Israel
  • Kaplan Medical Center
    Rehovot, 7610001, Israel
  • Ichilov Sourasky Medical Center; Heamatology
    Tel Aviv, 6423906, Israel
  • Az. Osp. Pugliese; Divisione de Ematologia
    Catanzaro, Calabria 88100, Italy
  • Ospedale Cardarelli; Divisione Di Ematologia
    Napoli, Campania 80131, Italy
  • Arcispedale S. Anna; Sezione Di Ematologia
    Ferrara, Emilia-Romagna 44100, Italy
  • IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica
    Meldola, Emilia-Romagna 47014, Italy
  • A.O. Universitaria Policlinico Di Modena; Ematologia
    Modena, Emilia-Romagna 41100, Italy
  • AUSL di Piacenza - Ospedale "Guglielmo da Saliceto";U.O. Ematologia
    Piacenza, Emilia-Romagna 29121, Italy
  • Az. Osp. S. Maria Delle Croci; U.O. Di Ematologia
    Ravenna, Emilia-Romagna 48100, Italy
  • Ospedale Infermi Di Rimini; Unità Operativa di Oncologia e Oncoematologia
    Rimini, Emilia-Romagna 47900, Italy
  • Universita' Degli Studi La Sapienza-Ist.Di Ematologia; Dip Biot Cel e Ematol
    Roma, Lazio 00161, Italy
  • Uni Degli Studi Di Genova; 1A Divisione Di Ematologia
    Genova, Liguria 16132, Italy
  • Ospedale Maggiore Di Milano; U.O. Ematologia I - Padiglione Marcora
    Milano, Lombardia 20122, Italy
  • ASST GRANDE OSPEDALE METROPOLITANO NIGUARDA; Struttura Complessa di Ematologia
    Milano, Lombardia 20162, Italy
  • Univ. Piemonte Est Amedeo Avogadro; Div.Ematologia- Dip.Clinica Med.Sperim.& Ircad
    Novara, Piemonte 28100, Italy
  • Ospedale Molinette - Universita' Di Torino; Cliniche Universitarie Ematologia I
    Torino, Piemonte 10126, Italy

Showing the first 100 of 174 sites across 31 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Stilgenbauer S, Bosch F, Ilhan O, Kisro J, Mahe B, Mikuskova E, Osmanov D, Reda G, Robinson S, Tausch E, Turgut M, Wojtowicz M, Bottcher S, Perretti T, Trask P, Van Hoef M, Leblond V, Foa R. Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study. Br J Haematol. 2021 Apr;193(2):325-338. doi: 10.1111/bjh.17326. Epub 2021 Feb 19. PubMed 33605445 ↗
  • Bosch F, Cantin G, Cortelezzi A, Knauf W, Tiab M, Turgut M, Zaritskey A, Merot JL, Tausch E, Trunzer K, Robson S, Gresko E, Bottcher S, Foa R, Stilgenbauer S, Leblond V. Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study. Leukemia. 2020 Feb;34(2):441-450. doi: 10.1038/s41375-019-0554-1. Epub 2019 Aug 27. PubMed 31455851 ↗
  • Stilgenbauer S, Leblond V, Foa R, Bottcher S, Ilhan O, Knauf W, Mikuskova E, Renner C, Tausch E, Woszczyk D, Gresko E, Lundberg L, Moore T, Morris T, Robson S, Bosch F. Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study. Leukemia. 2018 Aug;32(8):1778-1786. doi: 10.1038/s41375-018-0146-5. Epub 2018 Apr 27. PubMed 29749403 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2013 to primary completion in Dec 2016, 37 months.

Results were first posted in Oct 2018, 1 year 10 months after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 37 months is below that.

Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2013
First posted
Jul 23, 2013
StartActual
Nov 4, 2013
Primary completionActual
Dec 29, 2016
CompletionActual
Oct 8, 2018
Results first posted
Oct 29, 2018
Last update
Oct 28, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01905943
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 23, 2013
Start date
Nov 4, 2013
Primary completion
Dec 29, 2016
Completion
Oct 8, 2018
Results posted
Oct 29, 2018
Last update
Oct 28, 2019

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Obinutuzumab

Start the discussion